Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Begoña Benito Ibarrondo"'
Autor:
Ernesto Pérez‐Persona, Laida Cuevas Palomares, Ariane Unamunzaga Cilaurren, Xabier Gutiérrez López de Ocáriz, Buenaventura Buendía Ureña, Ana Vega González de Viñaspre, Begoña Benito Ibarrondo, María Carmen Molinillo Fernández, Ana Cordero Osúa, Beatriz Benítez Delgado, Juan José García Albás, Miguel Ángel Andrés Moralejo, José María Guinea de Castro
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 1196-1199 (2023)
Abstract In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day‐care hospital stays.
Externí odkaz:
https://doaj.org/article/3f5a1809b6f349108a18f7d0cc44f007
Autor:
Laida Cuevas Palomares, Ernesto Pérez, Ariane Unamunzaga Cilaurren, Xabier Gutierrez Lopez De Ocariz, Buenaventura Buendia Ureña, Carmen Molinillo Fernández, Begoña Benito Ibarrondo, Ana Cordero Osua, Beatriz Benitez Delgado, Miguel Andrés Moralejo, Juan García Albás, Jose Guinea de Castro
Publikováno v:
HemaSphere, Vol 7, p e102479d (2023)
Externí odkaz:
https://doaj.org/article/4ae7208947e84712b33917ed68eb0da2
Txagorrapid: Ultrarapid infusion in 30 minutes of the biosimilar of rituximab truxima—A cohort study
Autor:
Ernesto Perez Persona, Laida Cuevas Palomares, Ariane Unamunzaga Cilaurren, Xabier Gutierrez López de Gutierrez, Buenaventura Buendía Ureña, Carmen Luisa Molinillo Fernández, Begoña Benito Ibarrondo, Ana Isabel Cordero Osua, Beatriz Benítez Delgado, Miguel Angel Andrés Moralejo, Juan José García Albás, José María Guinea de Castro
Publikováno v:
Journal of Clinical Oncology. 40:e13638-e13638
e13638 Background: Rituximab (anti-CD20 Ab) is the cornerstone of the treatment of non-Hodgkin B lymphomas. Infusion-related reactions (IRR) are the most common adverse effects. To reduce them, intravenous premedication with antihistamine and acetami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1896d6a0d4def0641715697e7374211d
https://doi.org/10.1200/jco.2022.40.16_suppl.e13638
https://doi.org/10.1200/jco.2022.40.16_suppl.e13638